Abstract
Chemokines are key players in the attraction and activation of leukocytes and are thus implicated in the recruitment of immune cells at sites of infection and/or inflammation. They exert their action by binding to seven-transmembrane G protein-coupled receptors. The chemokine stromal cell-derived factor-1 (SDF-1)/CXCL12 represents the single natural ligand for the chemokine receptor CXCR4. CXCL12 possesses angiogenic properties and is involved in the outgrowth and metastasis of CXCR4-expressing tumors and in certain inflammatory autoimmune disorders, such as rheumatoid arthritis. CXCR4 expression on tumor cells is upregulated by hypoxia and angiogenic factors, such as vascular endothelial growth factor (VEGF). CXCR4 also acts as a co-receptor for entry of human immunodeficiency virus (HIV) in CD4+ T cells. Finally, CXCL12/CXCR4 interactions were shown to play an important role in the migration of hematopoietic stem cells and their progenitors from, and their retention within, the bone marrow, a site characterized by high CXCL12 expression. As such, CXCR4 inhibitors may be utilized to inhibit HIV-1 infection, tumor growth and metastasis and to mobilize hematopoietic stem cells from the bone marrow in the circulation, where they can be collected for autologous stem cell transplantation. Here, we discuss the different aspects of CXCL12/CXCR4 biology as well as the development and anti-cancer/stem cell mobilizing activity of CXCR4 antagonists.
Keywords: Angiogenesis, CXCL12, CXCR4, metastasis, progenitor cells, SDF-1, small molecule inhibitors, ELR, multiple myeloma, HUVEC, FGF-2, KR158, GL261, rheumatoid synovium, AMD3100, SCLC, Asp262, Glu288, non-Hodgkin's lymphoma, cholangiocarcinoma, acute lymphoblastic, acute myelogenous leukemia, bortezomib, melphalan, doxorubicin, dexamethasone, sorafenib, TN14003, MDA-MB-231, AMD070, WZ811, KRH-1636, KRH-3955, PRO2000, ALX40-4C, CTCE-9908, Plerixafor, BKT140, POL6326, TG-0054
Current Pharmaceutical Design
Title: CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Volume: 16 Issue: 35
Author(s): S. Liekens, D. Schols and S. Hatse
Affiliation:
Keywords: Angiogenesis, CXCL12, CXCR4, metastasis, progenitor cells, SDF-1, small molecule inhibitors, ELR, multiple myeloma, HUVEC, FGF-2, KR158, GL261, rheumatoid synovium, AMD3100, SCLC, Asp262, Glu288, non-Hodgkin's lymphoma, cholangiocarcinoma, acute lymphoblastic, acute myelogenous leukemia, bortezomib, melphalan, doxorubicin, dexamethasone, sorafenib, TN14003, MDA-MB-231, AMD070, WZ811, KRH-1636, KRH-3955, PRO2000, ALX40-4C, CTCE-9908, Plerixafor, BKT140, POL6326, TG-0054
Abstract: Chemokines are key players in the attraction and activation of leukocytes and are thus implicated in the recruitment of immune cells at sites of infection and/or inflammation. They exert their action by binding to seven-transmembrane G protein-coupled receptors. The chemokine stromal cell-derived factor-1 (SDF-1)/CXCL12 represents the single natural ligand for the chemokine receptor CXCR4. CXCL12 possesses angiogenic properties and is involved in the outgrowth and metastasis of CXCR4-expressing tumors and in certain inflammatory autoimmune disorders, such as rheumatoid arthritis. CXCR4 expression on tumor cells is upregulated by hypoxia and angiogenic factors, such as vascular endothelial growth factor (VEGF). CXCR4 also acts as a co-receptor for entry of human immunodeficiency virus (HIV) in CD4+ T cells. Finally, CXCL12/CXCR4 interactions were shown to play an important role in the migration of hematopoietic stem cells and their progenitors from, and their retention within, the bone marrow, a site characterized by high CXCL12 expression. As such, CXCR4 inhibitors may be utilized to inhibit HIV-1 infection, tumor growth and metastasis and to mobilize hematopoietic stem cells from the bone marrow in the circulation, where they can be collected for autologous stem cell transplantation. Here, we discuss the different aspects of CXCL12/CXCR4 biology as well as the development and anti-cancer/stem cell mobilizing activity of CXCR4 antagonists.
Export Options
About this article
Cite this article as:
Liekens S., Schols D. and Hatse S., CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455003
DOI https://dx.doi.org/10.2174/138161210794455003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Methotrexate Hepatotoxicity in Rheumatoid Arthritis: An Analysis of the Physicians’ Policy
Current Rheumatology Reviews Synthesis and In vivo Antifibrotic Activity of Novel Leflunomide Analogues
Letters in Drug Design & Discovery Synthesis of trans-fused Octahydroisoindole-1-carboxylic Acids
Letters in Organic Chemistry The CX3C-Chemokine Fractalkine in Kidney Diseases
Mini-Reviews in Medicinal Chemistry The MHC Genes in Psoriasis
Current Genomics Anti-angiogenesis Potential of Phytochemicals for the Therapeutic Management of Tumors
Current Pharmaceutical Design Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Current Pharmaceutical Biotechnology RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews Functional Properties of Pentacyclic Triterpenes Contained in "Orujo" Olive Oil
Current Nutrition & Food Science Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
Current Pharmaceutical Design Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology A Bioinorganic Perspective on Matrix Metalloproteinase Inhibition
Current Topics in Medicinal Chemistry Engineering of Therapeutic Proteins Production in Escherichia coli
Current Pharmaceutical Biotechnology How to Validate the Use of Musculoskeletal Ultrasound in Rheumatology for Clinical Trials
Current Rheumatology Reviews Monocyclic and Fused Azines and Azoles as Histamine H<sub>4</sub> Receptor Ligands
Current Medicinal Chemistry The ERK and p38MAPK Pathways as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery